Extending the Treatment Window for Intravenous Thrombolysis in Acute Ischemic Stroke: An Updated Systematic Review and Meta-Analysis
Расширение терапевтического окна для внутривенного тромболизиса при остром ишемическом инсульте: обновлённый систематический обзор и метаанализ
2026-09-11
SCID: 54.1/w2u8g6u2
Discuss with AI
acute ischemic strokeextended treatment windowimaging-based selectionintravenous thrombolysistenecteplase
Figures from the paper
Abstract (AI)
BACKGROUND AND OBJECTIVES: Intravenous thrombolysis (IVT) is the standard treatment for acute ischemic stroke within 4.5 hours of onset. However, imaging-based selection may extend the treatment window. This systematic review and meta-analysis evaluated the efficacy and safety of IVT administered beyond 4.5 hours after stroke onset or last known well (LKW) in patients selected based on imaging findings. METHODS: A comprehensive search of PubMed, Scopus, and Cochrane Library was performed to identify randomized controlled trials comparing IVT with alteplase or tenecteplase (TNK) administered >4.5 hours after stroke onset/LKW vs standard care. Primary outcomes were 3-month excellent (modified Rankin Scale [mRS] 0-1) functional outcome and symptomatic intracranial hemorrhage (sICH). Secondary outcomes included good (mRS 0-2) functional outcome, recanalization, and 3-month mortality. Pooled odds ratios (ORs) with 95% confidence intervals (CIs) were calculated using random-effects models. Subgroup analysis assessed differences between alteplase and TNK. RESULTS: = 0.11). DISCUSSION: Among patients selected based on imaging, 4.5-24 hours after stroke onset/LKW, IVT improves outcomes despite an increased risk of sICH. TNK showed similar efficacy to alteplase, with a possible lower risk of sICH; however, direct comparisons in future trials are needed.
Key Findings
1
Delayed intravenous thrombolysis was associated with an increased risk of symptomatic intracranial hemorrhage.
2
Imaging-based selection enabled evaluation of intravenous thrombolysis administered 4.5–24 hours after stroke onset or last known well.
3
In imaging-selected patients, delayed intravenous thrombolysis improved 3-month functional outcomes compared with standard care.
4
Tenecteplase showed similar efficacy to alteplase and a possible lower symptomatic intracranial hemorrhage risk, requiring direct comparative trials.
5
The abstract reports a randomized-trial systematic review and meta-analysis using pooled odds ratios with random-effects models.
Research Object
Imaging-selected patients with acute ischemic stroke treated with intravenous thrombolysis beyond 4.5 hours after stroke onset or last known well
Research Subject
The efficacy and safety of extended-window intravenous thrombolysis, including functional outcomes, symptomatic intracranial hemorrhage, recanalization, and mortality, with comparison of alteplase and tenecteplase
Publication Details
Publication Date
2026-09-11
Journal
Publisher
ISSN
Open access PDF
Access Type
Author Information
Download PDF
Subscribe to digest